Comparing Total Neoplasms, Breast & Prostate Cancer Mortality Rates of the UK and 20 Major Developed Countries 1989-91 v 2013-15 - Identifying Progress

C. Pritchard, B. Birch, T. Hickish, Emily Rosenorn-Lanng
{"title":"Comparing Total Neoplasms, Breast & Prostate Cancer Mortality Rates of the UK and 20 Major Developed Countries 1989-91 v 2013-15 - Identifying Progress","authors":"C. Pritchard, B. Birch, T. Hickish, Emily Rosenorn-Lanng","doi":"10.26502/AIMR.0050","DOIUrl":null,"url":null,"abstract":"Introduction: Britain’s cancer survival results have been criticised as being significantly higher than twenty Major Developed Countries (MDC). Hence this comparison of current UK Total Age-Standardised-Death-Rates (ASDR), female Breast and Prostate cancer mortality rates with twenty (MDC) between1989 to 2015 to determine any significant change. Method: WHO data ASDR per million (pm) for Total, Breast and Prostate cancer mortality rates examined for the years 1989-91 to 2013-15. Confidence Intervals (+/- 95%) are used to determine any significant differences between the UK and other country’s outcomes over the period. Chi square tests for each nation’s Breast and Prostate mortality. Results: Every country’s Total ASDR, Breast and Prostate cancer mortality fell except Greece and Japan. Total ASDR Male cancer mortality rates ranged from Portugal 1653pm to Sweden 1232pm. UK at 1475pm were 10th but had been 6th highest. Total ASDR Female rates went from Denmark’s 1176pm to Japan’s 740pm, the UK 1092pm now 5th but previously had been second highest. No country’s Total rates fell significantly more than Britain’s who had significantly bigger reductions than four other countries for both sexes. Breast mortality ranged from Ireland’s 206pm to Japan’s 99pm, UK rates fell significantly more than five countries. Whilst Breast mortality fell in every country Norway and UK had significantly bigger reductions in Breast than Prostate deaths, conversely France’s Prostate rates fell more than Breast mortality. Prostate mortality went from Norway 213pm Japan’s 60pm, the UK 167pm and five countries had greater reductions than Britain. Conclusions: Results reflect well on UK services for Total and Breast cancers, showing the NHS achieving more with proportionately less as Britain spends less on health than most MDC. The need how to improve UK prostate results are briefly discussed, such as a public information campaign to match the successful Breast cancer aware programme of the 1990’s.","PeriodicalId":8282,"journal":{"name":"Archives of Internal Medicine Research","volume":"151 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archives of Internal Medicine Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.26502/AIMR.0050","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Britain’s cancer survival results have been criticised as being significantly higher than twenty Major Developed Countries (MDC). Hence this comparison of current UK Total Age-Standardised-Death-Rates (ASDR), female Breast and Prostate cancer mortality rates with twenty (MDC) between1989 to 2015 to determine any significant change. Method: WHO data ASDR per million (pm) for Total, Breast and Prostate cancer mortality rates examined for the years 1989-91 to 2013-15. Confidence Intervals (+/- 95%) are used to determine any significant differences between the UK and other country’s outcomes over the period. Chi square tests for each nation’s Breast and Prostate mortality. Results: Every country’s Total ASDR, Breast and Prostate cancer mortality fell except Greece and Japan. Total ASDR Male cancer mortality rates ranged from Portugal 1653pm to Sweden 1232pm. UK at 1475pm were 10th but had been 6th highest. Total ASDR Female rates went from Denmark’s 1176pm to Japan’s 740pm, the UK 1092pm now 5th but previously had been second highest. No country’s Total rates fell significantly more than Britain’s who had significantly bigger reductions than four other countries for both sexes. Breast mortality ranged from Ireland’s 206pm to Japan’s 99pm, UK rates fell significantly more than five countries. Whilst Breast mortality fell in every country Norway and UK had significantly bigger reductions in Breast than Prostate deaths, conversely France’s Prostate rates fell more than Breast mortality. Prostate mortality went from Norway 213pm Japan’s 60pm, the UK 167pm and five countries had greater reductions than Britain. Conclusions: Results reflect well on UK services for Total and Breast cancers, showing the NHS achieving more with proportionately less as Britain spends less on health than most MDC. The need how to improve UK prostate results are briefly discussed, such as a public information campaign to match the successful Breast cancer aware programme of the 1990’s.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
比较1989- 1991年英国和20个主要发达国家的总肿瘤、乳腺癌和前列腺癌死亡率与2013- 2015年-确定进展
导读:英国的癌症存活率被批评为明显高于20个主要发达国家(MDC)。因此,对1989年至2015年英国总年龄标准化死亡率(ASDR)、女性乳腺癌和前列腺癌死亡率(MDC)进行比较,以确定是否有重大变化。方法:世卫组织1989-91年至2013-15年总死亡率、乳腺癌和前列腺癌死亡率的每百万人ASDR (pm)数据。置信区间(+/- 95%)用于确定英国和其他国家在此期间的结果之间的任何显著差异。每个国家乳腺癌和前列腺死亡率的卡方检验。结果:除希腊和日本外,各国的总ASDR、乳腺癌和前列腺癌死亡率均有所下降。总的ASDR男性癌症死亡率从葡萄牙下午1653分到瑞典下午1232分不等。英国在下午14点75分排名第十,但排名第六。女性的总ASDR比率从丹麦的1176上升到日本的740,英国的1092(目前排名第五,但之前是第二高)。没有哪个国家的总肥胖率比英国下降得多,英国的男女肥胖率都比其他四个国家下降得多。乳腺癌死亡率从爱尔兰的206pm到日本的99pm不等,英国的死亡率下降幅度明显超过5个国家。虽然每个国家的乳腺癌死亡率都在下降,但挪威和英国乳腺癌死亡率的下降幅度明显大于前列腺死亡率的下降幅度,相反,法国前列腺死亡率的下降幅度大于乳腺癌死亡率。前列腺死亡率从挪威的下午213分下降到日本的下午60分,英国的下午167分,还有五个国家的下降幅度比英国更大。结论:结果很好地反映了英国对乳腺癌和乳腺癌的服务,显示了NHS以更少的比例取得了更多的成就,因为英国在健康方面的花费比大多数MDC少。本文简要讨论了如何改善英国前列腺结果的必要性,例如开展公共信息运动,以配合20世纪90年代成功的乳腺癌意识方案。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Early vs Delayed Feeding after Endoscopic Esophageal Variceal Ligation: A Systematic Review and Meta-Analysis Effect of Andrographis paniculata Treatment for Nonimmune Patients with Early-Stage COVID-19 on the Prevention of Pneumonia: A Retrospective Cohort Study A New Anthropometric Model for Body Composition Estimation in the Assessment of Metabolic Risk Factors of Obese Women Demographic and Clinical Profile Analysis of Covid-19 Suspected Patients: A Tertiary Care Hospital Study in Bangladesh Cellular Uptake and Localization of Hematoporphyrin Derivatives in Lung Adenocarcinoma A549, Squamous Carcinoma H520 and Small Cell Carcinoma H446 Cell Lines
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1